Evaluation of the effectiveness of the drug Cytoflavin in patients with dyscirculatory encephalopathy who have undergone a new coronavirus infection

Close metadata

OBJECTIVE

To evaluate the effectiveness of the Cytoflavin in patients with dyscirculatory encephalopathy (DE) who had a new coronavirus infection.

MATERIAL AND METHODS

82 patients were examined: 16 (19.5%) men and 66 (80.5%) women aged 58 to 80 years, mean age 69±6 years and 70±6 years, respectively. All patients had moderate vascular cognitive impairment (less than 26 points according to the MoCA test), a history of COVID-19 in the period from 3 to 12 months before the start of the study. Patients before COVID-19 were registered with a neurologist with chronic cerebrovascular diseases with non-demented cognitive impairment of vascular origin. Patients of the main group (MG) received the Cytoflavin from the 1st to the 25^th day of observation, inclusive, 2 tablets 2 times a day against the background of standard basic therapy. Patients in the comparison group received only standard basic therapy.

RESULTS

It was found that during therapy with Cytoflavin, patients noted a positive trend in the form of a decrease in the symptoms of cognitive impairment, improved orientation and working memory, concentration of attention and counting. Also, patients in MG noted a decrease in fatigue and depressive disorders, an increase in motivation and a positive attitude, the emergence of interest in life, an improvement in the emotional background of mood, an increase in physical activity and working capacity. Comparing the mechanisms of development of vascular dysfunction, a pathogenetic commonality between DE and the development of consequences in the form of cognitive impairment caused by COVID-19 was noted.

CONCLUSION

Cytoflavin therapy at a dosage of 2 tablets 2 times a day for 25 days can be recommended as part of complex therapy for patients with DE and a COVID-19.

Keywords:

Cytoflavin

dyscirculatory encephalopathy

new coronavirus infection

cerebrovascular diseases

cognitive disorders

Authors:

Belova L.A.

Ulyanovsk State University

ORCID: 0000-0002-9585-5604

Mashin V.V.

Ulyanovsk State University

ORCID: 0000-0003-0085-3727

Dolgova D.R.

Ulyanovsk State University

ORCID: 0000-0001-5475-7031

Kuvayskaya A.A.

Ulyanovsk State University

ORCID: 0000-0002-2998-4344

Kruglova L.R.

Ulyanovsk State University

ORCID: 0009-0008-9665-6915

Sukhikh S.S.

Ulyanovsk State University

ORCID: 0009-0001-5137-0525

Plaksina T.D.

Ulyanovsk State University

ORCID: 0009-0004-4413-8324

Received:

10.04.2023

Accepted:

19.04.2023

List of references:

Moroz EV, Antonyuk MV. Rehabilitation potential in dyscirculatory encephalopathy (literature review). Bulletin of New medical technologies. [Electronic edition]. 2020;3. Publication 1-5. (In Russ.). https://doi.org/10.24411/2075-4094-2020-16530
Guryeva PV, Bykov YuN, Vasiliev YuN. Dyscirculatory encephalopathy textbook for doctors. FSUE VO IGMU of the Ministry of Health of Russia, Department of Nervous Diseases. Irkutsk: IGMU; 2017. (In Russ.).
Belova LA, Mashin VV. Venous disorders invariousformsof cerebral pathology. M., 2018. (In Russ.).
Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. BMJ. 2016;1(3):83-92. https://doi.org/10.1136/svn-2016-000035
Piradov MA, Tanashyan MM, Domashenko MA, Maksimova MYu. Nejroprotekciya pri cerebrovaskulyarnyh zabolevaniyah: poisk zhizni na Marse ili perspektivnoe napravlenie lecheniya? Annaly klinicheskoj i eksperimental’noj nevrologii. 2015;3(9):10-16. (In Russ.).
Gnedovskaya EV, Kravchenko MA, Prokopovich ME, et al Prevalence of the risk factors of cerebrovascular disorders in the capital city residents aged 40-59: a clinical and epidemiological study. Annaly klinicheskoi i eksperimental’noinevrologii. 2016;4(10):111-136. (In Russ.).
Joutel A, Chabriat H. Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms. Clin Sci (Lond). 2017;131(8):635-651. https://doi.org/10.1042/CS20160380
Mashin VV, Belova LA, Saprygina LV, et al. Risk Factors for cerebrovascular disease according to the screening of middle-aged population of Ulyanovsk. Annaly klinicheskoi i eksperimental’noi nevrologii. 2014;1(8):4-9. (In Russ.).
Belova LA, Mashin VV, Tararak TYa, Belov VG. The influence of cerebral venous discirculation. Uchenye zapiski UlGU, seriya «klinicheskaya meditsina». 2006;1(11):85-91. (In Russ.).
Gulevskaya TS, Morgunov VA. Ocherki angionevrologii. M.: Izdatel’stvo «Atmosfera». 2005. (In Russ.).
Belova LA, Mashin VV, Kolotik-Kameneva OIu, et al. Efficacy of cytoflavin in patients with hypertonic encephalopathy and constitutional venous insufficiency. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2012;112(8):21-26. (In Russ.).
Coronavirus disease (COVID-19). World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Respir Med. 2020;8(4):420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919-929. https://doi.org/10.1016/S1474-4422(20)30308-2
Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS‐CoV‐2 invasion as a port of central nervous system entry in individuals with COVID‐19. Nat Neurosci. 2021;24:168-175. https://doi.org/10.1038/s41593-020-00758-5
Kantonen J, Mahzabin S, Mäyränpää MI, et al. Neuropathologic features of four autopsied COVID‐19 patients. Brain Pathol. 2020;30:1012-1016. https://doi.org/10.1111/bpa.12889
Kirschenbaum D, Imbach LL, Rushing EJ, et al. Intracerebral endotheliitis and microbleeds are neuropathological features of COVID‐19. Neuropathol Appl Neurobiol. 2021;47(3):454-459. https://doi.org/10.1111/nan.12677
Li H, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide, and atherosclerosis. Atherosclerosis. 2014;237:208-219. https://doi.org/10.1016/j.Atherosclerosis.2014.09.001
Brown DI, Griendling KK. Regulation of signaling transduction by reactive oxygen species in the cardiovascular system. Circ Res. 2015;116:531-549. https://doi.org/10.1161/CIRCRESAHA.116.303584
Huang Y, Pinto MD, Borelli JL, et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: Looking for clarity in the haze of the pandemic. medRxiv. Published online March 5, 2021:2021.03.03.2125208. https://doi.org/10.1101/2021.03.03.21252086
Renaud-Charest O, Lui LMW, Eskander S, et al. Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. J Psychiatr Res. 2021;144:129-137. https://doi.org/10.1016/j.jpsychires.2021.09.054
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z
Afanas’ev VV, Beneskriptov IS. Lekarstvennye kombinatsii tsitoflavina s preparatami drugikh farmakologicheskikh grupp (v tablitsakh i skhemakh). SPb.: Taktik-Studio, 2016. (In Russ.).
Belova LA, Kolotik-Kameneva OYu, Mashin VV, et al. Condition of cerebral venous hemodynamics in patients with hypertonic encephalopathy with constitutional venous insufficiency in the process of neuroprotective therapy. Klinicheskaya fiziologiya krovoobrashcheniya. 2013;3:28-36. (In Russ.).
Belova LA, Kolotik-Kameneva OYu, Mashin VV, et al. Efficacy of the energy-modifier cytoflavin in the treatment of patients with hypertensive encephalopathy. Terapevticheskii arkhiv. 2014;9(86):65-71. (In Russ.).
Belova LA, Mashin VV, Kolotik-Kameneva OYu, Proshin AN. Cytoflavin Effect on Endothelium Function and Cerebral Hemodynamics in Patients with Hypertensive Enceplalopathy. Antibiotiki I khimioterapiya. 2014;7-8(59):30-36. (In Russ.).
Belova LA, Mashin VV, Kolotik-Kameneva OIu, et al. The influence of Cytoflavin therapy on the cerebral hemodynamics in patients with various stages of hypertensive disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(7):28-35. (In Russ.). https://doi.org/10.17116/jnevro20171177128-35
Mazin PV, Sheshunov IV, Mazina NK. Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3):28-39. (In Russ.). https://doi.org/10.17116/jnevro20171173128-39
Ekusheva EV, Voitenkov VB, Rizakhanova OA. The effectiveness of cytoflavin in complex therapy of patients with the coronavirus infection COVID-19. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(12):33-39. (In Russ.). https://doi.org/10.17116/jnevro202112112133
Petrova LV, Kostenko EV, Eneeva MA. Asthenia in the structure of postcovid syndrome: pathogenesis, clinic, diagnosis and medical rehabilitation. Doctor Ru. 2021;20(9):36-42. (In Russ.). https://doi.org/10.31550/1727-2378-2021-20-9-36-42
Al-Khani AM, Sarhandi MI, Zaghloul MS. A cross-sectional survey on sleep quality, mental health, and academic performance among medical students in Saudi Arabia. BMC Res Notes. 2019;21:12(1):665. https://doi.org/10.1186/s13104-019-4713-2
Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020;141:787-789. https://doi.org/10.1161/CIRCULATIONAHA.119.045256
Putilina MV, Vechorko VI, Grishin DV, Sidelnikova LV. Acute cerebrovascular accidents associated with SARS-CoV-2 coronavirus infection (COVID-19). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(12):109-117. (In Russ.). https://doi.org/10.17116/jnevro2020120121109
Petrey AC, Qeadan F, Middleton EA, et al. Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J Leukoc Biol. 2021;109:55-66.
Li D, Huang L-T, Zhang C-P, et al. Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment. Front. Aging Neurosci. 2022;14:890509. https://doi.org/10.3389/fnagi.2022.890509
Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2020;267(8):2179-2184. https://doi.org/10.1007/s00415-020-09929-7
Storch AS, de Mattos JD, Alves R, et al. Methods of Endothelial Function Assessment: Description and Applications. Int J Cardio Sci. 2017;30(3):262-273.
Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358(9286):971-976. https://doi.org/10.1016/S0140-6736(01)06104-9
Levite M. Glutamate receptor antibodies in neurological diseases: J Neural Transm (Vienna). 2014;121(8):1029-1075. https://doi.org/10.1007/s00702-014-1193-3
Voznyuk IA, Ponomarev GV, Kharitonova TV, et al. Diagnostic features of the level of antibodies to NR2-peptide in patients with chronic cerebral ischemia. Annals of Clinical and Experimental Neurology. 2021;15(2):5-12. (In Russ.). https://doi.org/10.25692/ACEN.2021.2.1
Pautz A, Li H, Kleinert H. Regulation of NOS expression in vascular diseases. Front Biosci. 2021;26(5):85-101. https://doi.org/10.52586/4926
Nguyen TMD. Adiponectin: Role in Physiology and Pathophysiology. Int J Prev Med. 2020;11:136. https://doi.org/10.4103/ijpvm.IJPVM_193_20

Close metadata